
Commentary|Videos|December 8, 2025
Catching Up on the Latest Data in CLL and Lymphoma With Drs Emmons, Brody, and Pinilla
Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.
Advertisement
Robert Emmons, MD, FACP, of the University of Louisville, Joshua Brody, MD, of The Tisch Cancer Institute at Mount Sinai, and Javier Pinilla, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, of Norton Cancer Institute, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.
Advertisement
Related to this article

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.

Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

An interim phase 1/2 trial update found that DB107-RRV plus DB107-FC could be given in combination with radiation in newly diagnosed high-grade glioma.
Advertisement
Advertisement
Trending on OncLive
1
Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLC
2
NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026
3
FDA Grants Breakthrough Therapy Designation to Daretabart for Newly Diagnosed High-Risk Neuroblastoma
4
Exploratory Insights into Early Tolerability and Treatment Experience with VYLOY® (zolbetuximab-clzb) in SPOTLIGHT and GLOW
5




